

Atty. Docket: PALMER=1

TECH CENTER 1600/2900

Conf. No.: 1664

1756 Art Unit:

Examiner:

Washington, D.C

May 9, 2002

ephen PALMER, et al 10/014,812 Appln. No.: Filed: December 14, 2001

re Application of:

For: METHOD OF INDUCING

OVULATION

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested That the information set forth in this statement and in the listed documents be considered during the pendency of the above- identified application, and any other application relying on the filing date of the above-identified application or cross- referencing it as a related application.

- This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed before the mailing date of a first office action on the merits.
- In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.

In re Appln. No. /014,812

- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Sheridan Neimark Reg. No. 20,520

SN:wlm:btd

624 Ninth Street, N.W., Suite 300 Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

F:\,S\Sern\Palmer1\Pto\Ids.doc

4	
ч	
٧.	•

Complete if Known Substitute for form 1449A/PTO 10/014,812 **Application Number** INFORMATION DISCLOSURE December 14, 2001 Filing Date Stephen PALMER et al. STATEMENT BY APPLICANT **First Named Inventor** Group Art Unit 1664 (use as many sheets as necessary) Confirmation No. Attorney Docket Number PALMER=1 of 3 Sheet 1

	-
OIPE	Ex lni
MAY. 0 9 2002	
TA TRADEMARK	

Examiner

Signature

				U.S. PATENT DOCU	MENTS	
U.S. Patent Documer			Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	AA	6,100,270		CAMPBELL	8-8-2000	
1	AB	6,316,472	B1	FRENETTE, et al	11-13-2001	
,	AC	6,316,457	B1	GARVEY, et al	11-13-2001	Ö
}	AD	6,303,789		BÄR, T.	10-16-2001	7 -
	AE	5,087,615		CHAPPEL, S.	2-11-1992	₩ 5
	AF	6,316,472		FRENETTE et al	11-13-2001	<u> </u>
	AG	5,710,160		GUAY, et al	1-20-1998	H 4
	AH	5,710,170		GUAY, et al	1-20-1998	
						8 5
						/29
						Š

				FOREIG	N PATENT DOCUMEN	rs		
Examiner Initials*	Cite No.1	Foreign Patent Number Kind Code ⁵ Office ³ Number (if known)		Kind Code Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶	
*	Al	wo	98/02440		BRÄUNLICH, et al	1-22-1998		
	AJ	wo	98/14432		FREYNE, et al	4-9-1998		
í	AK	wo	98/18796		HERSPERGER, R.	5-6-1998		
,	AL	wo	97/48697		COX, et al	12-24-1997		
,	AM	wo	97/44036		DYKE, et al	11-27-1997		
	AN	wo	97/44322		DYKE, et al	11-27-1997		
,	AO	wo	97/44337		DYKE, et al	11-17-1997	A	
4	AP	wo	98/20007		DYKE, et al	5-14-1998	30	
^	AQ	wo	97/42174		MARFAT, A.	11-13-1997	(C)~	
•	AR	wo	97/49702		MARFAT, A.	12-31-1997	MAY	1
							10 13 200	
	-						700	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

orm 1449A/PTO	Complete if Known							
	Application Number	10/014,812						
MATION DISCLOSURE	Filing Date	December 14, 2001						
MENT BY APPLICANT	First Named Inventor	Stephen PALMER et al.						
	Group Art Unit	1756						
use as many sheets as necessary)	Confirmation No.	1664						
of 3	Attorney Docket Number	PALMER=1	コノ					
OTHER PRIOR ART - NON	PATENT LITERATURE DO	OCUMENTS	유					
item (book, magazine, journal, serial, sy	mposium, catalog, etc.), date, page	e(s), volume-issue number(s),	006 2/0091 UB INEC					
	iRITO, et al, "Type 4 Phosphodiesterase Inhibitors and their Potential in the Treatment of Inflammatory Disease", Chapter 12, Emerging Drugs: The Prospect for Improved Medicines, Ashley Publications Ltd., ISSN 361-9195: 2:249-268 (1997).							
CONTI, M., "Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine Cells", Molecular Endocrinology, 14(9):1317-1327 (2000).								
COOKE, G.M. "Differential Effects of Trilostane and Cyanoketone on the 3 Beta-Hydroxysteroid Dehydrogenase- Isomerase Reactions in Androgen and 16-Androstene Biosynthetic Pathways in the Pig Testis", <u>J Steroid</u> Biochem Mol Biol 58:1 95-101 (1996).								
M. FILICORI, "Ovulation Induction: Gonadotropin-Releasing Hormone and Its Agonists", Reproductive Endocrinology, Surgery, and Technology, Volume 2, Chapter 61, Lippincott-Raven Publishers, Philadelphia (1996).								
		nology, Surgery, and Technology,						
HASSAN, et al, "Phosphodiesterase Inhibitor Improved Responsiveness to Gonadotropins In Low Responders", Fertility & Sterility, S249: 489, Alexandria ICSI-IVF Center, Alexandria, Egypt.								
KARLSSON, et al. "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(9):989-1003 (1997).								
			B. C.					
NORMAN, P., "PDE4 Inhibitors 1999", Exp. Op 1101-1118 (1999).	<u>oin. Ther. Patents,</u> Ashley Publica	ations Ltd., ISSN 1354-3776, 9(8):	90					
O'DONNELL, J., "William Harvey Research Col Therapeutic Uses", <u>Exp. Opin. Invest. Drugs</u> , A	nference on PDE Inhibitors: Dru shley Publications Ltd., ISSN 13	gs with an Expanding Range of 154-3784, 9(3):621-625 (2000).						
Inhibitors: Celltech Therapeutics Ltd.: WO972	3460 & WO9723461", Exp. Opii							
	MATION DISCLOSURE MENT BY APPLICANT Ise as many sheets as necessary) of 3 OTHER PRIOR ART - NON Include name of the author (in CAPI item (book, magazine, journal, serial, sy publisher, BRITO, et al, "Type 4 Phosphodiesterase Inhibi Disease", Chapter 12, Emerging Drugs: The P 1361-9195: 2:249-268 (1997). CONTI, M., "Phosphodiesterases and Cyclic Not 14(9):1317-1327 (2000). COOKE, G.M. "Differential Effects of Trilostan Isomerase Reactions in Androgen and 16-Androgen Mol Biol 58:1 95-101 (1996). M. FILICORI, "Ovulation Induction: Gonadotrop Endocrinology, Surgery, and Technology, Volun (1996). S. FRANKS et al., "Ovulation Induction: Gonadotrop Endocrinology, Surgery, and Technology, Volun (1996). S. FRANKS et al., "Ovulation Induction: Gonadotrop Endocrinology, Surgery, and Technology, Volun (1996). KARLSSON, et al. "Pulmonary-Allergy, Dermathashley Publications Ltd., ISSN 1354-3776, 7(9) MOVSESIAN, M., "Therapeutic Potential of Cyclesp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3776, 7(9) MOVSESIAN, M., "Therapeutic Potential of Cyclesp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3776, 7(9) MOVSESIAN, M., "Therapeutic Potential of Cyclesp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3776, 7(9) MOVSESIAN, M., "Therapeutic Potential of Cyclesp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355 "Patent Evaluation: Nicotinamide Derivatives as WO9845268", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355 "Patent Evaluation: Substituted Indazole Derivative Contents of Patent E	Application Number Filing Date First Named Inventor Group Art Unit Ise as many sheets as necessary) of 3 Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DO Include name of the author (in CAPITAL LETTERS), title of article (whe item (book, magazine, journal, serial, symposium, catalog, etc.), date, page publisher, city and/or country where published BRITO, et al, "Type 4 Phosphodiesterase Inhibitors and their Potential in the Tro Disease", Chapter 12, Emerging Drugs: The Prospect for Improved Medicines. 1361-9195: 2:249-268 (1997). CONTI, M., "Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine 14(9):1317-1327 (2000). COOKE, G.M. "Differential Effects of Triiostane and Cyanoketone on the 3 Bet Isomerase Reactions in Androgen and 16-Androstene Biosynthetic Pathways in Biochem Mol Biol 58:1 95-101 (1996). M. FILLCORI, "Ovulation Induction: Gonadotropin-Releasing Hormone and Its A Endocrinology, Surgery, and Technology, Volume 2, Chapter 61, Lippincott-Rav (1996). S. FRANKS et al., "Ovulation Induction: Gonadotropins", Reproductive Endocri Vol. 2, Chapter 60, Lippincott-Raven Publishers, Philadelphia (1996). HASSAN, et al., "Phosphodiesterase Inhibitor Improved Responsiveness to Gon Fertility & Sterility, S249: 489, Alexandria ICSI-IVF Center, Alexandria, Egypt. KARLSSON, et al. "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthr Ashley Publications Ltd., ISSN 1354-3776, 7(9):989-1003 (1997). MOVSESIAN, M., "Therapeutic Potential of Cyclic Nucleotide Phosphodiesterate Exp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3784, 9(5):963-4 "Patent Evaluation: Nicotinamide Derivatives as Selective Inhibitors of PDE4: F WO9845268", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355-1357 (1977). "Patent Evaluation: Nicotinamide Derivatives as Selective Inhibitors of PDE4: F WO9845268", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355-1357 (1977). "Patent Evaluation: Substituted Indazole Derivatives and thei	Application Number 10014,812 Filing Date December 14, 2001 First Named Inventor Stephen PALMER et al. Group Art Unit 1756 Confirmation No. 1664 The PALMER et al. Group Art Unit 1756 Confirmation No. 1664 The PALMER et al. The PALMER e					

Date

Considered

Examiner

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Substitute t	for form 1449A/PTO			С	omplete if Known	<u>m</u>	
			_	Application Number	10/014,812	王	
INFO	RMATION D	ISC	LOSURE	Filing Date	December 14, 2001	m	
STAT	EMENT BY	AP	PLICANT	First Named Inventor	Stephen PALMER et al.	3	
•				Group Art Unit	1756	2	_ <u></u>
	(use as many sheets	s as n	ecessary)	Confirmation No.	1664	7	
Sheet	3	of	3	Attorney Docket Number	PALMER≈1	8	L U

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the T² Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), nitials* publisher, city and/or country where published "Patent Evaluation: A Heterogeneous Collection of Novel Phosphodiesterase Type 4 Inhibitors", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 8(11):1529-1536 (1998). BG Patent Evaluation; Benzofuran and Quinoline Carboxamides and Quinoline Sulfonamides as TNF Inhibitors and as PDE4 inhibitors: Chiroscience Ltd.: WO9744337, WO9744036, WO9744322", Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 8(7):899-905 (1998). R. PHILOSOPHIE et al., "Gonadotropin-Induced Ovulation", Reproductive Endocrinology, Surgery, and Technology, Vol. 1, Chapter 54, Lippincott-Raven Publishers, Philadelphia (1996). SHETTY, et al. "Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates", J Steroid Biochem Mol Biol 61:3-6, 157-166 (1997). / VAN LOON, "In utero exposure to gonadotrophins", Female Infertility Therapy Current Practice, Chapter 1, SHOHAM, et al. (Eds.), Martin Dunitz Ltd., London (1999) Q BK SHUGHRUE et al., "Regulation of Progesterone Receptor Messenger Ribonucleic Acid in the Rat Medial Preoptic Nucleus by Estrogenic and Antiestrogenic Compounds: an in situ hybridization study", Endocrinology, 138:12, 1 5476-5484 (1999). BL A. TSAFRIRI et al., "Ovulation", Reproductive Endocrinology, Surgery, and Technology, Vol. 1, Chapter 11, Lippincott-Raven Publishers, Philadelphia (1996).) TURNER, et al., "Effect of Chronic Administration of an Aromatase Inhibitor to Adult Male Rats on Pituitary and Testicular Function and Fertility", <u>J Endocrinol</u>, 164:2, 225-238 (2000). A CHAPPEL et al., "Basic Knowledge About Recombinant Gonadotrophic Hormone Production", Female Infertility Therapy Current Practice, Chapter 9, SHOHAM, et al. (Eds.), Martin Dunitz Ltd., London (1999) RECEIVED

TO 1700

Examiner	Date	1
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.